China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions.
The pharmaceutical company AstraZeneca will file a request for approval of its novel coronavirus vaccine in the US later this year, the company said in a statement
An Imperial College London start-up has tied up with British-Swedish biopharmaceutical major AstraZeneca to explore the therapeutic uses of its vaccine technology
Drug firm AstraZeneca Pharma India on Sunday said it has received import and market permission from the Indian drug regulator for Selumetinib capsules. The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing. The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added. Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.
Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met
There aren't many places left for the COVID-19 virus to mutate and evade immunity as it will only get weaker with time, said the creator of the Oxford-AstraZeneca vaccine
Private hospitals and clinics will give their paying patients the option to receive their second dose of the vaccine 4 weeks after the first, down from between 12 and 16 weeks currently, say sources
British cell therapy firm makes announcement.
The EU has its own safe-travel list, from which the United States was recently removed after a spike in infections there.
The UK's health regulator has approved Pfizer and AstraZeneca vaccines for booster doses against Covid-19, even as the country's decision on the third dose remains pending.
The deal ends a blame game over the EU's slow start in vaccinating its 448 million population
Monoclonal antibodies boost immune response to infections by binding to particular sites on the spike protein of the virus that causes Covid-19.
Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports
SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said
A second wave of Covil infections and local supply delays prompted the government to prioritize its own citizens and halted overseas shipments of vaccines in April.
Preliminary results from Azerbaijan trials have been announced
Results from Astra's study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement Friday
The Oxford University study found that 90 days after a second shot of the Pfizer or Astra vaccine, their efficacy in preventing infections had slipped to 75 per cent and 61 per cent, respectively
The COVID vaccines by Pfizer and AstraZeneca are less effective against the Delta variant compared to the Alpha variant, according to a study led by researchers at the University of Oxford
Drug firm AstraZeneca Pharma India on Monday reported a 45.03 per cent decline in its net profit to Rs 10.24 crore for the June ended quarter